Skip to main content

Table 1 Patient Characteristics1

From: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease

N

62

Age (years)

47.4 ± 1.36

Male (%)

51

BMI (kg/m2)

36.8 ± 0.96

 BMI < 25 (%)

1.6

 BMI 25 ≤ x < 30 (%)

17.7

 BMI ≥30 (%)

80.6

NAS2 (0–8)

4 (3–5.25)

 Steatosis (0–3)

2 (1–3)

 Inflammation (0–3)

1 (0–1)

 Ballooning (0–2)

1 (0–2)

Fibrosis2 (0–4)

1 (0–1.25)

MG-H1 (pmol/mg protein)

0.902 ± 0.050

sRAGE (pg/ml)

565.6 ± 19.5

ALT (IU)

66.35 ± 6.82

ALP (IU)

85.61 ± 3.76

Bilirubin (μmol/L)

11.79 ± 1.4

Cholesterol (mmol/L)

5.08 ± 0.19

TAG (mmol/L)

2.07 ± 0.23

T2D (%)

19.4

HBP (%)

35.5

  1. 1Mean ± SEM except as noted; 2median with 25% - 75% percentile. Abbreviations: BMI, body mass index; NAS, NAFLD activity score; MG-H1, methylglyoxal-hydroimidazolone 1; sRAGE, soluble receptor for advanced glycation endproducts; ALT, alanine aminotransferases; ALP, alkaline phosphatase; TAG, triacylglycerol; T2D, type 2 diabetes; HBP, high blood pressure.